Round One To U.S. FDA In Ranbaxy’s Valcyte, Nexium Lawsuit
This article was originally published in PharmAsia News
Executive Summary
A Washington, D.C. Court has backed the U.S. FDA, which blocked tentative approvals granted to Ranbaxy for two drugs. But the closely watched case is still wide open, say experts.